Acurx Pharmaceuticals Aktie

0,3555 EUR -0,0160 EUR -4,31 %

15:29:02

FSE

0,4150 USD +0,0110 USD +2,72 %

18:12:02

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.10,26 Mio. EUR

Div. Rendite0,00%

WKNA3CSCG

ISINUS00510M1045

SymbolACXP

Acurx Pharmaceuticals Aktien News

Sortieren:Datum Meistgelesen

23.04.24PR NewswireAcurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update

18.03.24PR NewswireAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

04.03.24PR NewswireAcurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update

27.02.24PR NewswireAcurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development

29.01.24PR NewswireAcurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients

23.01.24PR NewswireAcurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024

17.01.24PR NewswireAcurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients

03.01.24PR NewswireAcurx to present at the 42nd Annual J.P. Morgan Healthcare Conference

11.12.23PR NewswireAcurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure

14.11.23PR NewswireAcurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update

02.11.23PR NewswireAcurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection

25.10.23PR NewswireAcurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Update

19.10.23PR NewswireAcurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences

02.10.23PR NewswireAcurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection

12.09.23PR NewswireAcurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress

22.08.23PR NewswireAcurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023

14.08.23PR NewswireAcurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update

24.07.23PR NewswireAcurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business Update

20.06.23PR NewswireAcurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023

15.06.23PR NewswireAcurx Pharmaceuticals to Participate in the Maxim Group LLC Virtual Healthcare Conference on Tuesday, June 20, 2023 to Thursday, June 22, 2023 at 9 am ET

12.05.23PR NewswireAcurx Pharmaceuticals, Inc. Reports First Quarter 2023 Results and Provides Business Update

05.05.23PR NewswireAcurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business Update

19.04.23PR NewswireAcurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference

11.04.23PR NewswireFDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference

16.03.23PR NewswireAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

06.03.23PR NewswireAcurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update

16.01.23PR NewswireAcurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023

14.11.22PR NewswireAcurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update

01.11.22PR NewswireAcurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022 Conference Call and Provide Business Update

26.10.22PR NewswireAcurx Announces Scientific Oral and Poster Presented at IDWeek 2022

17.10.22PR NewswireAcurx Announces Scientific Oral and Poster Presentations at IDWeek

15.08.22PR NewswireAcurx Pharmaceuticals, Inc. Reports Second Quarter 2022 Results and Provides Business Update

04.08.22PR NewswireAcurx Pharmaceuticals, Inc. to Discuss 2022 Second Quarter Financial Results on August 16, 2022 Conference Call and Provide Business Update

02.08.22PR NewswireAcurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of America

Acurx Pharmaceuticals News

Acurx Pharmaceuticals News: auf dieser Seite finden Sie alle Acurx Pharmaceuticals News und Nachrichten zur Acurx Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Acurx Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Acurx Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.